by Richard Daverman, PhD
May 9, 2013 -- Hutchison Chi-Med expects to license global rights to fruqintinib, one of its novel small-cell cancer drugs, before year-end, according to CEO Christian Hogg. The company has been in due diligence discussions with potential partners, he added. Because the drug is a promising treatment for solid tumors, Chi-Med will conduct simultaneous clinical trials against several types of cancer, and the company wants a partner to help shoulder the financial burden. More details....
Stock Symbol: (AIM: HCM)
